SG11202000312UA - Encapsulated polynucleotides and methods of use - Google Patents
Encapsulated polynucleotides and methods of useInfo
- Publication number
- SG11202000312UA SG11202000312UA SG11202000312UA SG11202000312UA SG11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- polynucleotides
- oncorus
- massachusetts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32041—Use of virus, viral particle or viral elements as a vector
- C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532886P | 2017-07-14 | 2017-07-14 | |
| US201862648651P | 2018-03-27 | 2018-03-27 | |
| PCT/US2018/042136 WO2019014623A1 (en) | 2017-07-14 | 2018-07-13 | Encapsulated polynucleotides and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000312UA true SG11202000312UA (en) | 2020-02-27 |
Family
ID=65002120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000312UA SG11202000312UA (en) | 2017-07-14 | 2018-07-13 | Encapsulated polynucleotides and methods of use |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200224220A1 (https=) |
| EP (1) | EP3652325A4 (https=) |
| JP (2) | JP2020530778A (https=) |
| KR (1) | KR20200036873A (https=) |
| CN (1) | CN111212914A (https=) |
| AU (1) | AU2018301701A1 (https=) |
| BR (1) | BR112020000839A2 (https=) |
| CA (1) | CA3069821A1 (https=) |
| IL (1) | IL271969A (https=) |
| MX (1) | MX2020000495A (https=) |
| RU (1) | RU2020106730A (https=) |
| SG (1) | SG11202000312UA (https=) |
| WO (1) | WO2019014623A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| CN111867609A (zh) * | 2018-03-12 | 2020-10-30 | 梅约医学教育与研究基金会 | 用感染性核酸治疗癌症 |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| MX2021005448A (es) * | 2018-11-13 | 2021-08-11 | Oncorus Inc | Polinucleotidos encapsulados y metodos de uso. |
| JP2022516318A (ja) * | 2019-01-04 | 2022-02-25 | オンコラス， インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
| WO2020185298A1 (en) * | 2019-03-14 | 2020-09-17 | Massachusetts Institute Of Technology | Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof |
| US20220267799A1 (en) * | 2019-08-05 | 2022-08-25 | Virogin Biotech Canada Ltd | Genetically modified enterovirus vectors |
| CA3157063A1 (en) * | 2019-10-10 | 2021-04-15 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
| CA3180557A1 (en) * | 2020-05-29 | 2021-12-02 | Lorena Lerner | Encapsulated rna replicons and methods of use |
| US20240261381A1 (en) * | 2020-06-11 | 2024-08-08 | Etherna Immunotherapies Nv | Lipid nanoparticles |
| US20230242994A1 (en) * | 2020-07-10 | 2023-08-03 | Shanghai Miran Biotech Co., Ltd. | Fluorescent cross-linked rnase h mutant conjugate, mirna combination and application thereof |
| WO2022150485A1 (en) * | 2021-01-06 | 2022-07-14 | Oncorus, Inc. | Encapsulated rna polynucleotides and methods of use |
| CN113368261A (zh) * | 2021-06-17 | 2021-09-10 | 苏州大学 | 一种非病毒载体及其制备方法与应用 |
| WO2023069948A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2023225371A1 (en) * | 2022-05-20 | 2023-11-23 | Virogin Biotech Canada Ltd | Genetically modified enterovirus vectors with enhanced genomic stability |
| JP7229412B1 (ja) | 2022-06-14 | 2023-02-27 | キユーピー株式会社 | 脂質ナノ粒子及びその製造方法 |
| CN118634238A (zh) * | 2022-06-27 | 2024-09-13 | 浙江大学 | 抗口腔肿瘤药物活性成分及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028658A2 (en) * | 2003-05-28 | 2005-03-31 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with a polii promoter and ribozymes |
| MXPA06003318A (es) * | 2003-09-26 | 2006-06-08 | Novartis Ag | Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad. |
| US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| GB0810912D0 (en) * | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
| CN102227503B (zh) * | 2008-09-26 | 2015-10-21 | 托卡根公司 | 重组载体 |
| JP6025567B2 (ja) * | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療 |
| WO2013083753A2 (en) * | 2011-12-07 | 2013-06-13 | Institut Pasteur | Identification of a swine parecho-like virus and applications |
| CA2868238A1 (en) * | 2012-04-18 | 2013-10-24 | Ramot At Tel Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
| JP6396891B2 (ja) * | 2013-04-17 | 2018-09-26 | 新日本製薬株式会社 | 遺伝子改変コクサッキーウイルス |
| US10513711B2 (en) * | 2014-08-13 | 2019-12-24 | Dupont Us Holding, Llc | Genetic targeting in non-conventional yeast using an RNA-guided endonuclease |
| AU2016274655B2 (en) * | 2015-06-10 | 2021-06-17 | NeoTrail Therapeutics, Inc. | HPV vaccines |
| WO2017096201A1 (en) * | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
-
2018
- 2018-07-13 KR KR1020207004226A patent/KR20200036873A/ko not_active Ceased
- 2018-07-13 CN CN201880057021.3A patent/CN111212914A/zh active Pending
- 2018-07-13 US US16/630,990 patent/US20200224220A1/en not_active Abandoned
- 2018-07-13 EP EP18832967.6A patent/EP3652325A4/en not_active Withdrawn
- 2018-07-13 AU AU2018301701A patent/AU2018301701A1/en not_active Abandoned
- 2018-07-13 SG SG11202000312UA patent/SG11202000312UA/en unknown
- 2018-07-13 MX MX2020000495A patent/MX2020000495A/es unknown
- 2018-07-13 CA CA3069821A patent/CA3069821A1/en active Pending
- 2018-07-13 BR BR112020000839-7A patent/BR112020000839A2/pt not_active Application Discontinuation
- 2018-07-13 WO PCT/US2018/042136 patent/WO2019014623A1/en not_active Ceased
- 2018-07-13 RU RU2020106730A patent/RU2020106730A/ru unknown
- 2018-07-13 JP JP2020523236A patent/JP2020530778A/ja active Pending
-
2020
- 2020-01-12 IL IL271969A patent/IL271969A/en unknown
-
2023
- 2023-09-27 JP JP2023166265A patent/JP2023165916A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3652325A4 (en) | 2021-09-15 |
| MX2020000495A (es) | 2020-08-20 |
| JP2023165916A (ja) | 2023-11-17 |
| CN111212914A (zh) | 2020-05-29 |
| IL271969A (en) | 2020-02-27 |
| BR112020000839A2 (pt) | 2020-07-21 |
| JP2020530778A (ja) | 2020-10-29 |
| CA3069821A1 (en) | 2019-01-17 |
| US20200224220A1 (en) | 2020-07-16 |
| EP3652325A1 (en) | 2020-05-20 |
| KR20200036873A (ko) | 2020-04-07 |
| AU2018301701A1 (en) | 2020-02-27 |
| WO2019014623A1 (en) | 2019-01-17 |
| RU2020106730A (ru) | 2021-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11202000274RA (en) | Oligonucleotide compositions and methods thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906147VA (en) | Optimized strategy for exon skipping modifications using crispr/cas9 with triple guide sequences | |
| SG11201805835WA (en) | Modified oncolytic virus | |
| SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201805805VA (en) | Recombinogenic nucleic acid strands in situ | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |